Peptide
Protirelin (TRH)
Protirelin is a synthetic tripeptide identical to hypothalamic thyrotropin-releasing hormone (TRH). FDA-approved for diagnostic assessment of thyroid function. Differentiates central from primary hypothyroidism. 90% of TSH-secreting adenomas show blunted TRH response vs normal response in thyroid hormone resistance. Peak TSH response at 20-30 minutes. Half-life ~5 minutes.
- Updated
- How we grade
- 22 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 6
- Graded outcomes
- 3012
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Depression Symptoms 7 preclinical studies support this finding. Primarily preclinical evidence. | Improves (the measure goes down) | Small effect | 8 studies | |||
Studies that measured depression symptoms
| ||||||
| Immune Function 2 preclinical studies support this finding. Primarily preclinical evidence. | Improves (the measure goes up) | Small effect | 3 studies | |||
| Blood Glucose Control 2 human trials support this finding. Human clinical trial data available. | Improves (the measure goes down) | Small effect | 3 studies | |||
Key findings
- Central Hypothyroidism DiagnosisImproves (the measure goes up)
- TSH Adenoma DetectionImproves (the measure goes up)
- Pituitary Function AssessmentImproves (the measure goes up)
Studies cited
22 studies from PubMed
- The TRH test provides valuable information in the diagnosis of central hypothyroidism in patients with known pituitary disease and low T4 levels
- Thyroid axis activity and dopamine function in depression.
- The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience
- Are the thyroid and adrenal system alterations linked in depression?
- The diagnosis and management of central hypothyroidism in 2018
- TRH and TRH receptor system in the basolateral amygdala mediate stress-induced depression-like behaviors.
- 2013 European Thyroid Association Guidelines for the Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors
- Novel thyrotropin-releasing hormone analogs: a patent review.
- Pituitary tumours: TSH-secreting adenomas
- The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis.
- TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes.
- Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology
- Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health
- The clinical impact of the thyrotropin-releasing hormone test
- Thyrotropin-releasing hormone (TRH): insulin-like action on glucoregulation.
- Multiple hormonal responses to protirelin (TRH) in depressed patients
- Dexamethasone suppression, protirelin stimulation, and insulin infusion in subtypes of recovered depressive patients.
- Immunoreactivity and serum destruction of N3immethyl-trh.
- Oral protirelin (T.R.H.) in depression.
- Protirelin stimulation test and thyroid function during treatment of depression.
- Protirelin (TRH) in depression.
- Dose-response studies with protirelin